Our Partners





Photos 2008

  ATGQ-Montreal Symposium Program (pdf)

May 2nd, 2010
13:00 Registration
13:50Welcoming Address
Dr. Rénald Gilbert
NRC Biotechnology Institute, Montréal, Québec
Session 1 Retroviral Vectors and Genome Modification - Chair Jeffrey Medin
14:00Dr. Manuel Caruso
Université Laval, Québec, Québec
Generation and Characterization of High-Titer Retrovirus Packaging Cell Lines that can Grow in Suspension and Serum-Free Media
14:30Dr. Amine Kamen
NRC Biotechnology Research Institute, Montréal, Québec
Development of a Scalable Process for High Yield Lentiviral Vector Production by Transient Transfection of HEK293 Suspension Cultures
15:00Dr. Jeffrey Medin
University of Toronto / University Health Network, Toronto, Ontario
Updates on Novel Cell Fate Control Systems
15:30Dr. John Bell
Ottawa Hospital Research Institute, Ottawa, Ontario
Multipronged Attack against Cancer with a Replicating Vaccine Virus Therapeutic
16:00Coffee Break
16:15Plenary Speaker
Dr. Keith Joung
Massachusetts General Hospital, Massachusetts, Boston
Engineered Zinc Finger Nucleases for Targeted Genome Modification
17:15Free Time
19:00Dinner
20:30Plenary Speaker
Dr. Kyri Mitrophanous
Oxford BioMedica, the Medawar Center, Oxford, U.K.
Gene Therapy in Parkinson Disease: from Pre-Clinical Studies in Primates
to a Phase I/II Clinical Trial

Lundi, 3 mai 2010 Monday May 3rd, 2010
Session II Gene Replacement and AAV Vectors Président / Chair Amine Kamen
08:30Dr. Jacques Tremblay
Université Laval, Québec, Québec
Meganucleases can Restore the Reading Frame of a Mutated Dystrophin
09:00Dr.Christine Hough
Queen's University, Kingston, Ontario
A MicroRNA-Regulated and GP64-Pseudotyped Lentiviral Vector Mediates Stable Expression of FVIII in Murine Model of Hemophilia A
09:30Dr. Marc Aucoin
University of Waterloo, Waterloo, Ontario
Advances in AAV Production in Insect Cells: What we Know now that we didn't Know then
10:00Coffee Break
10:15Mr. Alexander Bello
Public Health Agency of Canada, Winnipeg, Manitoba
Isolation and Performance of Novel Porcine AAVs
10:45Plenary Speaker
Dr. Alberto Auricchio
Federico II , University of Naples / Telethon Institute of Genetics and Medicine, Napoli
Gene Therapy of Inherited Retinal Diseases
12:00Lunch
Session III Adenovirus and Vaccination Président / Chair Gary Kobinger
13:30Dr. Daniel Jung
Héma-Québec / Université Laval, Québec, Québec
Intracellular Trafficking of Ad5 and Ad5/F35 Adenovirus in Normal Human B Lymphocytes and Human Myeloma Cell Lines U266
14:00Dr. Stephanie Swift
McMaster University, Hamilton, Ontario
Immunobiology of Recombinant Adenovirus Vectors
14:30Dr. Gary Kobinger
Public Health Agency of Canada, Winnipeg, Manitoba
Evaluation of Mismatched Immunity to Expand Cross-Protection against Influenza Virus
15:00Coffee Break
15:15Plenary Speaker
Dr. Frank Plummer
Public Health Agency of Canada, Winnipeg, Manitoba
HIV Resistance in Exposed Individuals
16:15Free Time
17:00Session d'affiches / Poster Session
19:00Dinner

Mardi, 4 mai 2010 Tuesday May 4th, 2010
Session IV Adenovirus/Cancer therapy Président / Chair Josephine Nalbantoglu
08:30Ms. Ami Patel
Public Health Agency of Canada, Winnipeg, Manitoba
Evaluation of a Porcine Adenovirus 3 Vector as Candidate for Rapid Vaccination against Avian Influenza H5N1
08:45Mr. Maxime Pinard
NRC Biotechnology Institute, Montréal, Québec
Improved Tropisms of Adenoviral Vectors for IGF-IR Positive Cells Using a Bispecific Ligand
09:00Dr. Rénald Gilbert
NRC Biotechnology Institute, Montréal, Québec
Gene Therapy of Duchenne Muscular Dystrophy with Improved Adenoviral Vectors
09:30Dr. Joséphine Nalbantoglu
Institut Neurologique de Montréal - McGill, Montréal, Québec
Differential Response of Glioma Cells to FOXO1-Directed Therapy
10:00Poster Awards
10:10Coffee Break
10:30Dr. Pnina Brodt
Royal Victoria Hospital, Montreal, Quebec
IGF-Trap-Based Therapy
11:00Plenary Speaker
Dr. Richard Vile
Mayo Clinic, Rochester, Minnesota
Tumour Immunology and Oncolytic Virotherapy: Wedded for Life, But for Better or for Worse?
12:00Lunch and conclusion